In an interview with Capital Market Laboratories (CMLviz), Chief Financial Officer of Veeva Systems (VEEV) Tim Cabral had a clear message: For Veeva, the opportunities are as big as they've ever been. The "Vault" suite of applications has only reached about ten percent of the addressable market in life sciences, and what took Veeva to a billion dollars will fuel the next several billion.

2019 Veeva R&D Summit — An increasing number of emerging biopharma companies and leading contract research organizations (CROs) are adopting Vault CDMS from Veeva Systems (VEEV) to manage their clinical data. More life sciences organizations are using Veeva Vault CDMS for multiple clinical trials to drive greater speed and agility in study execution. Vault CDMS is a modern cloud application for clinical data management that combines EDC, coding, data cleaning, and reporting on a single cloud platform.

Veeva Systems (VEEV) today announced that OPKO Health (OPK), a diagnostic and pharmaceutical company, selected multichannel Veeva CRM to enable field teams to engage in relevant, timely, and compliant interactions with healthcare professionals (HCPs) through preferred channels. Veeva CRM gives OPKO Health the most advanced capabilities and complete customer insights. “Veeva CRM helps our field teams better understand our customers in real time so we can engage more effectively and efficiently in the right channel,” said Adria Parks-Herrera, senior marketing director at OPKO Health.

Veeva Systems (NYSE:VEEV) just released its Q2 numbers and they were very good. The thing is, VEEV stock didn't really respond to its blowout earnings, revenue, and upbeat guidance.Source: IgorGolovniov / Shutterstock.com Why? Well, some of it has to do with the fact that VEEV stock is up 84% year to date. Analysts have been bullish on the niche cloud solutions provider for a while, so this great news didn't come from out of the blue.The stock is up over 1% today, but you need to bear in mind that VEEV stock is sporting a trailing PE of 89, so it's right in line with analysts' expectations. On the other hand, those expectations are high because VEEV has come to dominate a very important market sector.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Demand Boosts VEEV StockBasically, Veeva Systems has cloud-based software solutions for pharmaceutical, life sciences, and research companies that manage drug trials, research, as well as sales and distribution information. That includes content management systems that allow varied access of the sales side to the R&D side.Being able to share this highly proprietary data across an organization in a secure and efficient way is crucial. And building cloud-based systems specifically for the unique needs of this sector has allowed VEEV to build a groundswell of demand for its products.Remember that big pharmaceutical companies used to be vertically integrated behemoths, with massive internal structures. But increasingly, they have spun off divisions to companies that specifically focus on drug trials, product development, or manufacturing.All this subdivisions and subcontractors mean communications have become evermore important. And visibility is essential.According to a study by Johns Hopkins Bloomberg School of Public Health, drug trials alone cost about $19 million. But according to a study by Tufts Center for the Study of Drug Development, the total cost of getting a drug to market, including R&D, production, marketing, etc, is around $2.6 billion.That's why it's crucial for companies to manage their resources wisely. And one of the keys to that is having real time information at their fingertips. Resilient Healthcare Sector Solidifies VEEV StockAnother point to bear in mind here is that VEEV stock isn't really affected by the bigger global issues that are tugging on other stocks right now. The trade war with China and the Brexit furor don't really change its growth path.The only thing that may change its trajectory would be a significant global slowdown or U.S. recession. But even then, healthcare is one of the more resilient sectors, especially as the populations of major industrialized countries are getting older and relying on more medications to boost the quality of their older citizens.What's more, animal medicines are also in great demand. For example, the African Swine Flu is having a major effect on pork production in Europe and Asia. Drug therapies to stem this quickly rising tide of infections is vital to these economies.It's no surprise then that VEEV stock remains an A-rated stock in my Portfolio Grader.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off * 7 'Strong Buy' Stocks to Beat Volatility * 7 Mega-Cap Tech Stocks on a Rebound Now The post Veeva Stock Proves Itas Still Going Strong appeared first on InvestorPlace.

Veeva Systems (VEEV) today announced a new quality risk management (QRM) capability in Veeva Vault QMS. Life sciences companies can now take a proactive approach to monitoring risks and implementing mitigation plans throughout the entire product lifecycle for enhanced product quality and patient safety.

An increasing number of contract research organizations (CROs) are adopting Veeva Development Cloud applications from Veeva Systems (VEEV) in an industrywide drive to improve efficiency, compliance, and collaboration in working with sponsors and sites. More than 55 CROs, including 6 of the top 7 global CROs, are modernizing their clinical, regulatory, and quality processes to accelerate drug development. “We have significantly improved our trial efficiency by streamlining clinical operations with Veeva Vault eTMF,” said Julie Ross, president at Advanced Clinical.

Veeva Systems fell after undercutting its 50-day line on Friday. (VEEV, daily) volatile after earnings. Still in a base with a 177 flat base buy point.STOCK MARKET TODAY is sponsored by Interactive Brokers. To open an account, go to ibkr.com/whyib